TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23824978

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment after 24 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) treatment after 60 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cumulative CAB dose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prolactin levels normalization
Number of subjects: 40
Study: 23826832

Group type: EXPERIMENTAL
Intervention: Lumbar support pillow
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard chair
Number of subjects: 28
Study: 23827036

Group type: EXPERIMENTAL
Intervention: Routine culture for mycobacteria during bronchoscopy
Number of subjects: 362
Study: 23827886

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 10 weeks
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Genetic ancestry analysis
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Socioeconomic and baseline clinical factors
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Race (self-reported)
Number of subjects: 1877
Study: 23828026

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23828202

Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) during VOC
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Biochemical markers during VOC
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Biopsy inflammation at steady-state
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tricuspid regurgitation velocity (TRV) at steady-state
Number of subjects: 23
Study: 23828252

Group type: EXPERIMENTAL
Intervention: 1,020 mg of ferumoxytol administered over 15 min
Number of subjects: 60
Study: 23829205

Group type: EXPERIMENTAL
Intervention: HbA1c-MEAN
Number of subjects: 8290

Group type: EXPERIMENTAL
Intervention: HbA1c-SD
Number of subjects: 8290

Group type: EXPERIMENTAL
Intervention: HbA1c-MEAN and HbA1c-SD
Number of subjects: 8290
Study: 23829485

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) infusion of veltuzumab (80-320 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injections of veltuzumab (80-320 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both IV and SC administration of veltuzumab
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injections of veltuzumab
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Veltuzumab treatment
Number of subjects: 41
Study: 23829956

Group type: EXPERIMENTAL
Intervention: Bipedicled nerve flap with nerve graft from the dorsal branch of the digital nerve
Number of subjects: 9
Study: 23830159

Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach) infusion (10(-6) to 10(-4))
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (200 μg)
Number of subjects: 25
Study: 23830564

Group type: EXPERIMENTAL
Intervention: Manual segmentation and computer-assisted techniques for detecting drusen regression
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fundus photography
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fundus autofluorescence (FAF) imaging
Number of subjects: 58
Study: 23831416

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (cisplatin 80 mg/m(2) on day 1, cisplatin 70 mg/m(2) on days 8, 15, 29, 36, 43, 57, 64; doxorubicin 30 mg/m(2) on days 8, 9, 36, 37, 57, 58) followed by surgery.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Surgical removal of all remaining tumour lesions if feasible.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (doxorubicin 20 mg/m(2) on days 1, 2, 22, 23, 43, 44; carboplatin AUC 6·6 mg/mL per min on days 1, 22, 43) for patients who did not receive cycle B.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (including preoperative and postoperative chemotherapy).
Number of subjects: 62
Study: 23831596

Group type: EXPERIMENTAL
Intervention: Autologous myoblast transplantation
Number of subjects: 12
Study: 23831734

Group type: EXPERIMENTAL
Intervention: AZD0865 25-75 mg/day
Number of subjects: 2875

Group type: COMPARATOR
Intervention: Esomeprazole 20 or 40 mg/day
Number of subjects: 2875
Study: 23831756

Group type: EXPERIMENTAL
Intervention: 30 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 60 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 120 mg oral ∆(9)-tetrahydrocannabinol (THC)/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Smoked cannabis challenge (five puffs)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ad libitum cannabis smoking
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral cavity contamination after smoking or oromucosal spray
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: THCCOOH ratios
Number of subjects: 11
Study: 23831922

Group type: EXPERIMENTAL
Intervention: LALA94/GRAALL03-05 protocols
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CALM-AF10 fusion within early T-cell precursor acute lymphoblastic leukemia
Number of subjects: 22
Study: 23832926

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including a health coach and enhanced personal health record
Number of subjects: 229

Group type: COMPARATOR
Intervention: Routine discharge care (Control)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 229
Study: 23833039

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-exposed SLE women
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control SLE women
Number of subjects: 112
Study: 23833120

Group type: EXPERIMENTAL
Intervention: Weekly low-dose chloroquine (5 mg/kg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 23834234

Group type: EXPERIMENTAL
Intervention: Single-agent lenalidomide
Number of subjects: 266
Study: 23834337

Group type: EXPERIMENTAL
Intervention: Poststroke dementia
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Poststroke cognitive impairment-no dementia
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Stroke recurrence
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 600
Study: 23834901

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3737
Study: 23834999

Group type: EXPERIMENTAL
Intervention: Mobile device users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional web browser users
Number of subjects: 0
Study: 23836520

Group type: EXPERIMENTAL
Intervention: SAT 11βHSD1 expression in African Americans
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SAT 11βHSD1 expression in combined sample
Number of subjects: 36

Group type: COMPARATOR
Intervention: SAT 11βHSD1 expression in Hispanics
Number of subjects: 36
Study: 23836798

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) performed with Symplicity Catheter System (n=6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the remaining patients who did not receive RDN)
Number of subjects: 18
Study: 23837399

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (three doses)
Number of subjects: 0
Study: 23837440

Group type: EXPERIMENTAL
Intervention: Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Child Health Assessment Questionnaire (CHAQ)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire (CHQ)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Health Utilities Index 3 (HUI3)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison with other paediatric populations
Number of subjects: 96

Group type: COMPARATOR
Intervention: General comparison with normative values
Number of subjects: 96
Study: 23837759

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (TDM-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab and taxanes
Number of subjects: 0
Study: 23837842

Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Number of subjects: 36
Study: 23838219

Group type: EXPERIMENTAL
Intervention: Indwelling catheters
Number of subjects: 7866

Group type: EXPERIMENTAL
Intervention: External catheters
Number of subjects: 7866

Group type: EXPERIMENTAL
Intervention: Overall urinary catheter use
Number of subjects: 7866

Group type: EXPERIMENTAL
Intervention: Acute medicine wards
Number of subjects: 7866

Group type: EXPERIMENTAL
Intervention: Infection control reporting
Number of subjects: 7866
Study: 23838767

Group type: EXPERIMENTAL
Intervention: Glaucoma patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 23838996

Group type: EXPERIMENTAL
Intervention: Ganetespib
Number of subjects: 0
Study: 23839074

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 5 cmH2O with tripled tidal volume during LBNP40
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal breathing without PEEP or tripled tidal volume during baseline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal breathing without PEEP or tripled tidal volume during LBNP40
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal breathing without PEEP or tripled tidal volume during LBNP15
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) 40 mmHg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) 15 mmHg
Number of subjects: 14
Study: 23839484

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg co-administered with bosutinib 400 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bosutinib 400 mg alone
Number of subjects: 24
Study: 23840001

Group type: EXPERIMENTAL
Intervention: Initial challenge with C. jejuni CG8421
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Second challenge with C. jejuni CG8421
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Immune responses after primary infection
Number of subjects: 15
Study: 23840124

Group type: EXPERIMENTAL
Intervention: Mitochondrial ATP 6 and 8 polymorphisms in patients with IBS-D
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mitochondrial DNA change at 8860
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 8701 polymorphism
Number of subjects: 28
Study: 23840618

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (first dose) in ART naïve subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (second dose) in ART naïve subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (first dose) in subjects on ART
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (two doses) in ART naïve subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Safety evaluation (local and systemic AEs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Monitoring of CD4 count and HIV RNA load
Number of subjects: 24
Study: 23841031

Group type: EXPERIMENTAL
Intervention: Rigosertib (ON 01910.Na) administered as a 3-day continuous infusion every 2 weeks at escalating doses (50, 100, 150, 250, 325, 400, 650, 850, 1,050, 1,375, 1,700 mg/m(2)/24h).
Number of subjects: 28
Study: 23842023

Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System (DHFS)
Number of subjects: 28
Study: 23842041

Group type: EXPERIMENTAL
Intervention: Sunitinib therapy
Number of subjects: 23
Study: 23842457

Group type: EXPERIMENTAL
Intervention: Noniodized salt
Number of subjects: 9412

Group type: EXPERIMENTAL
Intervention: Mild salt appetite
Number of subjects: 9412

Group type: EXPERIMENTAL
Intervention: Neither iodized salt nor milk
Number of subjects: 9412

Group type: EXPERIMENTAL
Intervention: Low urinary iodine concentration (UIC)
Number of subjects: 9412
Study: 23844897

Group type: EXPERIMENTAL
Intervention: Risk factors for recurrence
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Risk factors for life-threatening complications
Number of subjects: 322
Study: 23845947

Group type: EXPERIMENTAL
Intervention: Lentiviral gene therapy using a lentiviral vector encoding functional WASP
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lentiviral gene therapy
Number of subjects: 3
Study: 23845948

Group type: EXPERIMENTAL
Intervention: Lentiviral gene therapy using a lentiviral vector to transfer a functional ARSA gene into hematopoietic stem cells (HSCs)
Number of subjects: 3
Study: 23846249

Group type: EXPERIMENTAL
Intervention: Commercial assay for ADAMTS13 activity measurement
Number of subjects: 0
Study: 23846776

Group type: EXPERIMENTAL
Intervention: 150 mg oral dose of dabrafenib
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) microdose of 50 µg radiolabeled dabrafenib
Number of subjects: 4
Study: 23847271

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy (endoscopic therapy combined with non-selective β-blockers and anticoagulants)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 50
Study: 23847319

Group type: EXPERIMENTAL
Intervention: Ultrahigh-resolution optical coherence tomography
Number of subjects: 26
Study: 23849084

Group type: EXPERIMENTAL
Intervention: Cortisol measurement in women with a current or recent experience of abuse
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cortisol measurement in women living in refuge
Number of subjects: 128

Group type: COMPARATOR
Intervention: Cortisol measurement in abuse survivors
Number of subjects: 128
Study: 23850249

Group type: EXPERIMENTAL
Intervention: Non-fibroatheroma lesions
Number of subjects: 609

Group type: COMPARATOR
Intervention: Fibroatheroma lesions
Number of subjects: 609
Study: 23850394

Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mirabegron 100mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mirabegron (both doses)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 23850901

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 54
Study: 23850908

Group type: EXPERIMENTAL
Intervention: Successful cardioversion without anticoagulation or peri-procedural heparin therapy
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2481

Group type: EXPERIMENTAL
Intervention: Classification tree analysis
Number of subjects: 2481
Study: 23851165

Group type: EXPERIMENTAL
Intervention: Stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SID-LC/ESI/SRM/MS method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxylamine derivatization procedure coupled with tandem mass spectrometry
Number of subjects: 0
Study: 23851388

Group type: EXPERIMENTAL
Intervention: Osteopontin combined with NT-proBNP
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Osteopontin
Number of subjects: 401

Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 401
Study: 23851911

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily plus Darunavir/Ritonavir 800/100 mg once daily
Number of subjects: 15
Study: 23852419

Group type: EXPERIMENTAL
Intervention: NR3C2 mutation carriers
Number of subjects: 39
Study: 23852775

Group type: EXPERIMENTAL
Intervention: H-1 parvovirus (H-1PV) infection
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-transformed infant astrocytes and neurons
Number of subjects: 6
Study: 23855804

Group type: EXPERIMENTAL
Intervention: Cetuximab administered as loading dose and then weekly during radiotherapy (exact dosage not specified)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT) or 3D-dimensional radiation therapy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Translational research program
Number of subjects: 500
Study: 23856024

Group type: EXPERIMENTAL
Intervention: Treatment for inherited surfactant metabolism disorders (specific treatment details not provided)
Number of subjects: 0
Study: 23856681

Group type: EXPERIMENTAL
Intervention: 100 mg of alternate-day aspirin
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 23856802

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Continued medical management
Number of subjects: 242
Study: 23857643

Group type: EXPERIMENTAL
Intervention: Restorations placed in previously unrestored tooth surfaces
Number of subjects: 4672

Group type: EXPERIMENTAL
Intervention: Outcomes within individual patients (tooth surfaces affected by caries lesions)
Number of subjects: 4672
Study: 23857959

Group type: EXPERIMENTAL
Intervention: Sepantronium Bromide (10 mg/m(2)/day, continuous intravenous infusion over 72 hours)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Carboplatin (AUC6) and Paclitaxel (200 mg/m(2))
Number of subjects: 41
Study: 23857966

Group type: EXPERIMENTAL
Intervention: Pazopanib (tablet formulation) administered once daily in 28-day cycles at four dose levels (275 to 600 mg/m(2))
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pazopanib (tablet formulation)
Number of subjects: 51
Study: 23860199

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg per day for 1 year
Number of subjects: 106

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 106
Study: 23860535

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m², Carboplatin AUC 5 mg/ml/min, Bevacizumab 15 mg/kg every 21 days for six cycles followed by maintenance Bevacizumab
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard pemetrexed/platinum combinations (not explicitly tested in this trial)
Number of subjects: 76
Study: 23860537

Group type: EXPERIMENTAL
Intervention: Lenvatinib 4 mg BID with carboplatin/paclitaxel
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lenvatinib 6 mg BID with carboplatin/paclitaxel
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lenvatinib with carboplatin/paclitaxel
Number of subjects: 28
Study: 23861180

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI treatment)
Number of subjects: 0
Study: 23861247

Group type: EXPERIMENTAL
Intervention: T-cell receptor-engineered lymphocytes
Number of subjects: 0
Study: 23861248

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² IV) administered at 3, 6, 9, and 12 months after transplantation
Number of subjects: 65
Study: 23861512

Group type: EXPERIMENTAL
Intervention: OAC+ASA
Number of subjects: 7347

Group type: COMPARATOR
Intervention: OAC
Number of subjects: 7347
Study: 23863898

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (autoHSCT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Reinduction therapy followed by alloHSCT
Number of subjects: 124
Study: 23864214

Group type: EXPERIMENTAL
Intervention: Education programme targeted at school children to reduce salt intake, lasting approximately 4.5 months.
Number of subjects: 840

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 840
Study: 23865483

Group type: EXPERIMENTAL
Intervention: Standardized methods for data collection (anamnestic, clinical, laboratory, imaging, ultrasound) in ischemic stroke patients
Number of subjects: 400
Study: 23865516

Group type: EXPERIMENTAL
Intervention: Ubiquitin C-terminal hydrolase L1 (UCH-L1)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Glial fibrillary acidic protein (GFAP)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combined analysis of UCH-L1 and GFAP
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: GFAP
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: UCH-L1
Number of subjects: 206
Study: 23866070

Group type: EXPERIMENTAL
Intervention: Plasma fibulin-1 in diabetic group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Plasma fibulin-1 in control group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Total study sample analysis
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Adjusted analysis in diabetes group
Number of subjects: 180
Study: 23866188

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23866828

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day + reduced-dose cyclosporine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g/day + standard dose cyclosporine
Number of subjects: 122
Study: 23867137

Group type: EXPERIMENTAL
Intervention: Mexican-American adolescent women
Number of subjects: 559

Group type: COMPARATOR
Intervention: African-American adolescent women
Number of subjects: 559
Study: 23867211

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks with loading doses on days 8 and 15 of the first cycle (for cohorts 1 and 2)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks with loading doses on days 8 and 15 of the first cycle (for cohort 2)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 282
Study: 23867552

Group type: EXPERIMENTAL
Intervention: CD40L/IFN-γ-matured, IL-12p70-producing DCs
Number of subjects: 7
Study: 23867776

Group type: EXPERIMENTAL
Intervention: ROTEM analysis at T1 (10 min after heparin administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: INTEM at T0 compared to HEPTEM at T1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EXTEM and HEPTEM at T2 (end of CPB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EXTEM and INTEM at T3 (10 min after protamine)
Number of subjects: 20
Study: 23867999

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Deleterious BRCA1/2 mutation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cumulative exposure to carboplatin
Number of subjects: 87

Group type: COMPARATOR
Intervention: History of HSR
Number of subjects: 87
Study: 23868427

Group type: EXPERIMENTAL
Intervention: Intravenous injection of HPPH (4.0 mg/m2), followed by activation with 665-nm laser light in the surgical bed immediately after tumor resection.
Number of subjects: 16